Kira8
Kira8 is a mono-selective IRE1α inhibitor that allosterically attenuates IRE1α RNase activity (IC50: 5.9 nM) . (In Vitro) :Kira8 more effectively causes IRE1α-driven apoptosis in INS-1 cells than KIRA6 and also reverses XBP1 splicing promoted by GNF-2. Kira8 blocks IRE1α oligomerization and effectively inhibits IRE1α RNase activity against XBP1 and Ins2 RNAs. (In Vivo) :One week of treatment of pre-diabetic NODs mice with Kira8 (50 mg/kg; i.p.; once a day) causes obvious reductions in islet XBP1 splicing and TXNIP mRNAs. It also preserves Ins1/Ins2, BiP, and MANF mRNAs. Male Ins2+/Akita mice are injected i.p. with KIRA8 (50 mg/kg; daily; for 35 days), obviously reduction of hyperglycemia becomes apparent over several weeks.
Product Specifications
CAS Number
1630086-20-2
Product Name Alternative
AMG-18
Purity
>98% (HPLC)
Solubility
In Vitro: Ethanol : 76.92 mg/mL (127.96)
Smiles
Cc1ccc2c (NS (=O) (=O) c3ccccc3Cl) cccc2c1Oc1ncccc1-c1ccnc (N[C@H]2CCCNC2) n1
Molecular Formula
C31H29ClN6O3S
Molecular Weight
601.12
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Available Sizes
Explore Other Products
Browse additional items from our catalog